Author: Admin

Developer

Type-1 Diabetes – The Beginning of the End Close to a Cure

Posted on by Admin

In 1988 Dr. Camillo Ricordi (above) revolutionized a method of transplantation of islet cells (cells that produce insulin) which remains the gold standard for human pancreas processing today. The problem is, like with so many other types of transplantation, the body often rejects the new cells. All that could change with the introduction of this anti-rejection antibody – Novus Therapeutics, Inc. (NASDAQ:NVUS) – CD40/CD40L – FDA Phase II.

Join Dr. Ricordi and his world-class panel of experts who will weigh-in on the likelihood of this medical breakthrough. They’ll also look at what the future may hold for investors in the technology, and those who are considering an investment. It’s T1D-Day, with the hopeful surrender of this debilitating disease just around the corner.

November 24, 2020

Watch The Replay

Premium Content Available to Registered Users – Registration is Free

 

Panelists (left to right): Dr. Camillo Ricordi, Director of the Diabetes Research Institute at the University of Miami School of Medicine – Ranked as the World Leader in Islet Cell Transplant; Dr. James Markmann, Chief of the Division of Transplant Surgery and Director of Clinical Operations at the Transplant Center at Massachusetts General Hospital, and the Claude Welch Professor of Surgery at Harvard Medical School; Dr. Norma Sue Kenyon, Martin Kleiman Professor of Surgery, Microbiology and Immunology and Biomedical Engineering, Vice Provost for Innovation; Dr. David Gros, Chief Executive Officer Novus Therapeutics; Dr. Steven Perrin, President & CSO, Novus Therapeutics, and; Eric Paslay, award-winning country recording artist (T1 diabetic who will provide a patient perspective).

 

Moderator: Nathan Cali, Head of Healthcare Investment Banking, Noble Life Science Partners (a division of Noble Capital Markets).

 

November is National Diabetes Month, a time when communities across the country team up to bring attention to diabetes. This year’s focus is on taking care of youth who have diabetes.

 



Scientific support from:

©2020 Noble Capital Markets

Disclosures: Noble Capital Markets, Inc. (“Noble”) is a FINRA / SEC registered broker-dealer and the provider of equity research on Channelchek. On September 14, 2020, Novus Therapeutics, Inc.(“Novus”) acquired Anelixis Therapeutics, Inc. (“Anelixis”). Prior to the acquisition, and in the last twelve months, Anelixis retained Noble as a placement agent and financial advisor, and as such, Noble was compensated. In the next twelve months, Noble may be retained by Novus and receive compensation for services it may render. Nathan Cali, Head of Healthcare Investment Banking at Noble (moderator of the panel), was previously an Anelixis Observer Board Member. Dr. Camillo Ricordi (“Ricordi”) has been compensated by Noble as a Scientific Advisor in the past twelve months. Ricordi and Dr. James Markmann serve or have served as scientific advisors or consultants to Novus in the past twelve months. Ricordi has been compensated by Novus for his role. The T1D-Day panel is presented as informational only and does not constitute an offer or solicitation to buy or sell securities. There is no suggestion or obligation for attendees to act on any of the information discussed by the panel.

 


Members FINRA | SIPC | MSRB

Release – Lineage Cell Therapeutics (LCTX) – Presents New OpRegen Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting

Posted on by Admin

 

Lineage Cell Therapeutics Presents New Opregen® Data For Dry Amd With Ga At 2020 American Academy Of Ophthalmology Annual Meeting

 

  • Improved Visual Acuity Continues to be Observed in Cohort 4 Patients
  • First Known Clinical Report of Retinal Tissue Regeneration Persisted to 23 Months with Further Improvement in Visual Acuity
  • Patient Enrollment Recently Completed
  • Therapeutic Expert Call with Principal Investigator Christopher D. Riemann, M.D. Scheduled for November 17, 2020 at 4:00 pm Eastern Time

CARLSBAD, Calif.–(BUSINESS WIRE)–Nov. 16, 2020– Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious medical conditions, today announced positive interim results from the ongoing 24-patient Phase 1/2a clinical study of Lineage’s lead product candidate, OpRegen®. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). At AAO, new data were presented on 20 patients, including 8 patients treated in Cohort 4, which feature better baseline vision and smaller areas of GA. All 8 of these patients were treated with a new “thaw-and-inject” formulation of OpRegen and 4 were treated using the Gyroscope Orbit Subretinal Delivery System (Gyroscope SDS). Data presented at AAO showed improvements in visual acuity in Cohort 4 patients, with treated versus fellow eye comparisons reaching statistical significance at 9 and 12 months following OpRegen administration. These improvements were maintained for up to 24 months in some patients. A trend towards slower GA growth was observed in the first 6 Cohort 4 patients, a trend maintained for as long as 24 months in patients with 24-month data available. Previously reported structural improvements in the retina and decreases in drusen density have continued with evidence of durable engraftment of OpRegen cells in treated patients, some more than 4 years following administration, with no immunosuppression utilized beyond the perioperative period. Overall, OpRegen appears to be well-tolerated in all patients treated to date. The final four patients in the study were treated during November and will provide additional visual acuity data in the coming months.

“These new data increasingly suggest to us that treatment with OpRegen can provide clinically meaningful outcomes in dry AMD patients with GA, particularly for those with earlier-stage disease,” stated Brian M. Culley, Lineage CEO. “According to a recent survey published in Investigative Ophthalmology & Visual Science, only 27% percent of retinal specialists believed patients with visual acuity of 20/200 or worse could benefit from treatment with an agent which slows the growth of GA, while 93-99% of them believed patients with visual acuity of 20/200 or better could benefit from this approach. This is consistent with our belief that recent data from our Cohort 4 patients, which have less advanced disease and better baseline vision, are more exciting and provide a better surrogate for the potential clinical and commercial opportunity for OpRegen.”

Mr. Culley added, “In addition to reporting the first known finding of anatomical restoration of retinal tissue, which has persisted below baseline for 23 months and counting, treatment with OpRegen continues to demonstrate other benefits in some patients, including increases in visual acuity, reductions in the growth rate of GA and increases in reading speed. These are additive to the improvements we previously reported in retinal architecture and drusen reduction. Further, the multi-year durability of transplants without rejection is notable for our allogeneic cell therapy approach, especially as patients did not require long-term immunosuppression. With enrollment recently completed, our focus turns next toward collecting safety and efficacy data on the most recently treated patients, advancing partnership and investor discussions we’ve been having, exploring our options for later-stage clinical development, and speaking with the FDA about next steps. Our objective is to position the OpRegen program as a front-runner in the race to address an unmet need in what is widely expected to be a multi-billion-dollar dry AMD therapeutic market and to drive Lineage forward as the pre-eminent allogeneic cell therapy company.”

OpRegen Data Update & Highlights from the AAO Presentation (data presented on 20 patients, dosed through October 5, 2020):

  • Continued progressive functional improvement.
    • In Cohort 4, 6 out of 7 (86%) of patients’ treated eyes measured above their baseline vision (Best Corrected Visual Acuity, or BCVA) at 12 months, a clinically relevant timeframe, or as of the longest available timepoint less than 12 months (data collection continues for more recently-treated patients).
    • Data to date demonstrate a localized slowing of GA progression in the treated areas with a trend towards slower GA growth in treated versus fellow eyes in pooled analyses.
  • Long-term engraftment is supported with imaging observations up to more than 4 years, even with a short immunosuppression regimen.
    • In all Cohort 4 patients receiving OpRegen TAI formulation, per protocol, immunosuppressants have been discontinued as scheduled, typically within 90 days post-operatively, and no cases of acute or delayed rejection or inflammation have been reported.
    • One Cohort 4 patient was treated only with mycophenolate mofetil and received no tacrolimus for immunosuppression.
  • Anatomical restoration of retinal tissue.
    • A Cohort 4 patient with evidence of retinal restoration and confirmed history of GA growth, which was first reported at 9 months, continues at month 23 to have an area of GA smaller than at baseline.
    • This patient also experienced additional improvement in BCVA from 9 to 23 months post-treatment, while the untreated eye has experienced further reduction in visual acuity.
    • Long-term monitoring on this patient is expected to continue.
  • Treatment overview.
    • As of October 5, 2020, 16 patients were treated via pars planar vitrectomy (PPV), while 4 were treated with the Gyroscope SDS.
    • As of November 10, 2020, 17 patients were treated via PPV, while 7 were treated with the Gyroscope SDS.
    • Enrollment in the phase 1/2a study is complete; follow-up continues for safety and efficacy.
  • Safety and tolerability.
    • The primary objective of the study is to evaluate the safety and tolerability of OpRegen at 12 months, and in patients which have reached this time point OpRegen appears well tolerated.
    • There have been no unexpected adverse events (AEs) or treatment-related systemic serious AEs reported in enrolled patients.
    • The most common and expected ocular AEs were the formation or exacerbation of mild to moderate epiretinal membranes (ERMs) and a single report of a retinal detachment, with cause unknown (all occurring in patients receiving OpRegen via the PPV route of administration).
    • The Gyroscope SDS is an alternative to the PPV route and is designed to avoid ERM formation.
      • Through October 2020, 16 patients were treated via PPV while 4 were treated with the Gyroscope SDS. ERMs were observed in 13 PPV patients.
      • One patient treated with the Gyroscope SDS developed a mild choroidal neovascularization (CNV) at the site of needle penetration 6 months post-treatment which was successfully treated with a single dose of an approved anti-VEGF agent. The cause was unknown.
      • One patient treated via PPV developed a mild CNV at > 24 months post-treatment.
    • Other changes observed following OpRegen treatment persisted through the last time point examined (> 4 years in some patients), including subretinal pigmentation and hyper-reflective areas seen on optical coherence tomography (OCT).

The results were presented at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020). The presentation, “Phase 1/2a Study of Subretinally Transplanted hESC-Derived RPE Cells in Advanced Dry-Form AMD Patients” was featured as part of the Original Paper Session, OP02V Retina, Vitreous Original Papers on November 15, 2020 and was presented by Christopher Riemann, M.D.

KOL Call and Webcast

Lineage will host a therapeutic area expert call with Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine, to discuss the interim results on November 17, 2020 at 4:00 pm Eastern Time / 1:00 p.m. Pacific Time. Interested parties can access the event on the Events and Presentations section of Lineage’s website.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (vision from 20/65 to 20/250 with smaller areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. In total, 17 patients were treated via PPV, while 7 were treated with the Gyroscope SDS. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additionally, for the patients in Cohort 4 that receive subretinal delivery of OpRegen utilizing the Gyroscope SDS, objectives will include the evaluation of the safety of delivery of OpRegen using the Gyroscope SDS.

OpRegen is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of Lineage Cell Therapeutics, Inc.

About Dry AMD

Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of $10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s expected eligibility for grants. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the Securities and Exchange Commission (the SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s Annual Report on Form 10-K filed with the SEC on March 12, 2020 and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or David Schull
[email protected]
[email protected]
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.

Release – Cabral Gold (CBGZF, CBR.V) – Announces the Appointment of Carlos Vilhena to Board of Directors

Posted on by Admin

 

Cabral Gold Announces the Appointment of Carlos Vilhena to Board of Directors

 

Vancouver, British Columbia – November 16, 2020 – Cabral Gold Inc. (“Cabral” or the “Company”) (TSXV: CBR) (OTC: CBGZF) is pleased to announce the appointment of Carlos Vilhena to Cabral’s Board of Directors with immediate effect.

Carlos Vilhena is a partner at the law firm of Pinheiro Neto Advogados, based in Brasilia, Brazil, where he is the administrative managing partner of the local office. Mr. Vilhena also heads the firm’s mineral resources law and government relations practices.

For many years, he has provided legal advice to a large number of corporate clients including both major and junior mining companies and multilateral and commercial banks. This advice involved all areas related to the mineral resources sector, including regulatory, permitting, M&A, land, community and government relations, infrastructure, indigenous populations, processing, sales, tax, environment, power, contracts, corporate, financing, litigation legislative process, risk assessment and policy.

Mr. Vilhena has repeatedly been recognised as one of the top mining law practitioners in Brazil by a number of publications, including the International Who’s Who of Mining Lawyers published by Who’s Who Legal, the Latin Lawyer, Chambers and Legal 500.

He is a director of the Rocky Mountain Mineral Law Foundation and Co-Chair of the Mining Law Committee of the International Bar Association. He is a director of TriStar Gold Inc. Mr. Vilhena holds an LLM degree in Natural Resources Law from the Centre for Energy, Petroleum, and Mineral Law and Policy of the University of Dundee, Scotland and an LLB from the University of Brasilia Law School.

Alan Carter, Cabral’s President and CEO commented, “We are extremely pleased that Carlos has agreed to join the Board of Directors of Cabral. His position as a Partner and Head of Mineral Resources Law at one of Brazil’s largest law firms provides Cabral with a breadth of relevant experience and a wide network throughout the mining industry in Brazil. In short, he is uniquely qualified to assist us as we continue to advance the world-class Cuiú Cuiú district located in the Tapajos region of Para state”.

Issuance of Stock Options

Cabral’s Board of Directors has approved the granting of stock options to various employees, directors and consultants pursuant to the Company’s stock option plan. The stock options entitle the holders to purchase a total of 1,150,000 common shares in the capital stock of the Company at a price of $0.60 per common share. The stock options are exercisable for five years and are subject to vesting over 24 months.

About Cabral Gold Inc.

The Company is a junior resource company and is engaged in the identification, exploration and development of mineral properties, with a primary focus on gold properties located in Brazil. The Company has a 100% interest in the Cuiú Cuiú gold district located in the Tapajós Region, within the state of Pará in northern Brazil.

The Tapajós Gold Province is the site of the largest gold rush in Brazil’s history producing an estimated 30 to 50 million ounces of placer gold between 1978 and 1995. Cuiú Cuiú was the largest garimpo in the Tapajós and produced an estimate 2Moz of placer gold historically.

FOR FURTHER INFORMATION PLEASE CONTACT:

“Alan Carter”

President and Chief Executive Officer
Cabral Gold Inc.
Tel: 604.676.5660

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statements

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of the words “will”, “expected” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: strategic plans and future operations, and results of exploration. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct.

Source: Cabral Gold | Tel: 604-676-5660 | 1500 – 409 Granville Streeet, Vancouver, BC V6C1T2 Canada | www.cabralgold.com

Release – Palladium One Mining (NKORF) – Step-Out Drill Hole Intersects Shallow High-Grade Mineralization at Murtolampi Zone Finland

Posted on by Admin

 

Palladium One Step-Out Drill Hole Intersects Shallow, High-Grade Mineralization at Murtolampi Zone, Finland

 

November 16, 2020 – Toronto, Ontario – Starting at only 11 m down hole, hole LK20-026 at the Murtolampi Zone, intersected high-grade open pit potential mineralization returning 13 m at 3.4 g/t palladium equivalent (Pd_Eq)* within 79 m at 2.0 g/t Pd_Eq (Figure 1, 2 and 3). said Palladium One Mining Inc. (“Palladium One” or the “Company”) (TSXV: PDM, FRA: 7N11, OTC: NKORF) today.

Key highlights:

  • Shallow high-grade results suggest potential for a low-cost satellite open pit at Murtolampi, which is close to the existing Kaukua deposit, located 2 km to the south.
  • Murtolampi remains open for expansion both laterally and at depth.
  • A core, near surface interval of 13 m at 3.4 g/t Pd_Eq starting 66 m down hole in hole LK20-026 returned 79 m at 2.0 g/t Pd_Eq starting 11.0 m down hole.
  • Hole LK20-026 is located 50 m southwest of Hole LK20-012 which returned 20 m at 2.3 g/t Pd_Eq, starting 29 m down hole within 87 m @ 1.4 g/t Pd_Eq starting 5.8 m downhole (see news release dated August 25, 2020)
  • Hole LK20-026 is also located 550 m northeast of hole LK20-024 which returned a core interval of 3 m at 1.4 g/t Pd_Eq. within 21 m at 0.85 g/t Pd_Eq.
  • The mineralized peridotite at Murtolampi has now been defined over a 600 m strike length.

“The at surface mineralization at Murtolampi continues to advance a potentially valuable satellite pit to the Kaukua deposit which is located only 2 km to the south.” said Derrick Weyrauch, President and Chief Executive Officer. “Hole LK20-026 is by far the highest-grade hole drilled to date at Murtolampi, we look forward to additional results from this zone in the Phase II drill program.”

Palladium One has confirmed PGE-Ni-Cu mineralization over 600 m of strike length at the Murtolampi zone and the zone remains open for expansion laterally and at depth (Figure 1, 2 and 3).

The Murtolampi zone hosts both mineralized (holes LK20-12, 024 & 026) and unmineralized (hole (LK20-025) peridotite. Mineralized peridotite contains blebby Cu-Ni sulphides and strong PGE mineralization and produces a modest Induced Polarization (IP) chargeability anomaly. Unmineralized peridotite is Ni bearing and Cu-PGE-poor while containing fine grain disseminated pyrite which produces strong IP chargeability anomalies. These two peridotite phases are in contact with one another at Murtolampi, making distinctions between the IP anomalies difficult. The overall geometry of the Murtolampi zone is yet to be defined, additional holes including undercut and scissor holes are planned in the Phase II drill program to better define the mineralization peridotite body.

Phase II Drill Program

Based on its discovery success this year, the Company has launched a 17,500 m phase II diamond drill program (see news release November 10, 2020) which will be focused on the Kaukua South and Murtolampi zones.

Figure 1

This figure shows the greater Kaukua Area, the NI 43-101 compliant Kaukua Open Pit resource, Murtolampi and Kaukua South zones. Select resumed Phase I drill holes labelled in red.

Figure 2

Murtolampi Cross section showing hole LK20-012 looking southwest, showing IP Chargeability isoshells and Pd_Eq grade.

Figure 3

Murtolampi Long section looking northwest, showing IP Chargeability isoshells and Pd_Eq grade, resumed Phase I drill holes labelled in red.

Table 1: Resumed Phase 1 Drill Results from Murtolampi Zone

* Reported widths are “drilled widths” not true widths.
** Grey Italicised values are previously released (see press release August 25, 2020)

*Palladium Equivalent

Palladium equivalent is calculated using US$1,100 per ounce for palladium, US$950 per ounce for platinum, US$1,300 per ounce for gold, US$6,614 per tonne for copper, and US$15,4332 per tonne for nickel. This calculation is consistent with the calculation in the Company’s September 2019 NI 43-101 Kaukua resource estimate.

QA/QC

The Phase I drilling program was carried out under the supervision of Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company.

Drill core samples were split using a rock saw by Company staff, with half retained in the core box and stored indoors in a secure facility, in Taivalkoski, Finland. The drill core samples were transported by courier from the Company’s core handling facility in Taivalkoski, Finland, to ALS Global (“ALS”) laboratory in Outokumpu, Finland. ALS, is an accredited lab and are ISO compliant (ISO 9001:2008, ISO/IEC 17025:2005). PGE analysis was performed using a 30 grams fire assay with an ICP-MS or ICP-AES finish. Multi-element analyses, including copper and nickel were analysed by four acid digestion using 0.25 grams with an ICP-AES finish.

Certified standards, blanks and crushed duplicates are placed in the sample stream at a rate of one QA/QC sample per 10 core samples. Results are analyzed for acceptance at the time of import. All standards associated with the results in this press release were determined to be acceptable within the defined limits of the standard used

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43- 101.

About Palladium One

Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladium-dominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email:
[email protected]

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Source: Palladium One Mining Inc.

Release – Cocrystal Pharma (COCP) – Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

Posted on by Admin

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

 

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –

– Ongoing Merck collaboration to discover and develop influenza A/B antiviral agents –

– Continued advancement of wholly owned Influenza A development program and IND enabling studies towards Phase 1 clinical study in 2021–

– Successful completion of strategic financing fuels expansion of COVID-19 and Influenza A development programs –

 

BOTHELL, WA, Nov. 16, 2020 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended September 30, 2020 and provided program updates.

Recent Highlights

  • Announced promising in vitro and 7-day toxicity data for its influenza A preclinical lead molecule, CC-42344.
  • Announced new in vitro data demonstrating antiviral activity with lead compound CC-42344 against major Xofluza (baloxavir)-resistant H1N1 strain (I38T).
  • Presented at the virtual World Antiviral Conference held on November 12, 2020.
  • Closed $17.2 million bought deal including partial exercise of underwriter’s overallotment option.
  • Publication by collaborators of data demonstrating potent in vitro inhibition against Coronavirus in Science Translational Medicine Journal (August 3, 2020).

“We have made significant progress since initiating our COVID-19 program this year by strengthening our patent portfolio around these molecules, conducting a proof of concept animal study, initiating preclinical studies and identifying additional inhibitors using our proprietary platform. Over the course of the last quarter we continued to make progress on multiple fronts. We are pleased with the promising new data we recently announced for our wholly owned influenza A development program and continue to work towards finalizing the Phase 1 study protocol in preparation to initiate the Phase 1 study in 2021,” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. “In addition to advancing our development programs, we closed the quarter with $31.8 million cash, which provides funding for the expansion of our COVID-19 and influenza A programs. Our team remains keenly focused on executing our milestones to drive shareholder value.”

Development Programs Overview

COVID-19 Coronavirus Programs:
We have two programs that are aggressively pursuing the development of novel antiviral compounds for the treatment of coronavirus infections.

Our first program is with compounds licensed from Kansas State University Research Foundation (“KSURF”) that have demonstrated in vitro anti-SARS-CoV-2 (responsible for the COVID-19 pandemic) activity, and in vivo efficacy in MERS-CoV-infected animal models. Cocrystal continued preclinical studies of these COVID-19 inhibitors during the third quarter. We anticipate the selection of a lead preclinical molecule by the end of 2020.

Our second program in Covid-19 has identified additional inhibitors using Cocrystal’s proprietary platform technology.

We are evaluating multiple routes of administration of COVID-19 antivirals.

Influenza A/B Inhibitors: Merck Collaboration
We have an exclusive license and collaboration agreement with Merck to discover and develop proprietary influenza A/B antiviral agents.

Cocrystal’s exclusive license and collaboration agreement with Merck Sharp & Dohme Corp. (“Merck”) to discover and develop proprietary influenza A/B antiviral agents is ongoing. Merck has funded the collaborative influenza A/B program and could potentially provide up to $156 million in milestone payments through clinical and commercial development, plus royalties following commercialization.

The collaboration operates under a Research Operating Plan which includes goals for both organizations. The Company has achieved its anticipated goals through the third quarter of 2020.

CC-42344: Influenza A Program:
Novel, broad spectrum influenza antivirals that are specifically designed to be effective against pandemic and seasonal influenza A strains of the influenza virus and to have a high barrier to resistance due to its novel mechanism of action.

The Company’s fully owned drug candidate CC-42344 is a potent, broad spectrum inhibitor of the influenza replication enzyme targeting the PB2 subunit, and has strong synergistic effects when combined with approved influenza antiviral drugs including Tamiflu (oseltamivir) and Xofluza (baloxavir). Cocrystal has data showing that CC-42344 retained single digit nanomolar potency (EC50 = 0.5 nM) against a Xofluza (baloxavir) resistant influenza A strain (H1N1, I38T). This data can potentially show CC-42344 drug superiority when seeking FDA approval.

The Company plans to complete the ongoing IND-enabling studies and enter into clinical trials in 2021.

CC-31244: Hepatitis C Program:
Potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the ultra-short combination treatment of hepatitis C infection.

The Company is pursuing partnering opportunities for CC-31244. The final study report of Cocrystal’s U.S. Phase 2a clinical trial evaluating CC-31244 combination therapy for the ultrashort treatment of hepatitis C virus (“HCV”) infected individuals has been completed and filed with the FDA. The Company has published with its collaborators from the University of Maryland the results of the Phase 2a study (Journal of Medical Virology, November 5, 2020).

Norovirus Program:
Developing inhibitors targeting Norovirus RNA-dependent RNA polymerase and protease.

Cocrystal continues to identify and develop non-nucleoside polymerase and protease inhibitors using its proprietary structure-based drug design technology platform. Cocrystal recently entered into license agreements with KSURF to further develop proprietary broad-spectrum protease inhibitors to treat Norovirus and Coronavirus infections.

Summary of Financial Results for Q3 2020

As of September 30, 2020, Cocrystal had approximately $31,781,000 cash on hand.

Revenue recorded for the three and nine months ended September 30, 2020 was $489,000 and $1,504,000, respectively, compared with $492,000 and $6,162,000 for the three and nine months ended September 30, 2019, respectively. The revenue difference for the nine months ended September 30, 2019 is because that period included $4,368,000 in initial revenue of intellectual property rights conveyed at the signing of the Merck Collaboration Agreement executed on January 2, 2019.

Research and development expenses for the three and nine months ended September 30, 2020 were $2,077,000 and $5,336,000, respectively, compared with $1,077,000 and $3,046,000 for the three and nine months ended September 30, 2019, respectively. The increase for the three and nine months ended September 30, 2020 compared to the three and nine months ended September 30, 2019 was primarily due to initiating our COVID-19 program and advancing our Influenza A program in preparation for clinical trials in 2021.

General and administrative expenses for the three and nine months ended September 30, 2020 were $1,121,000 and $4,288,000, respectively, compared with $1,223,000 and $3,597,000 for the three and nine months ended September 30, 2019, respectively. The decrease for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily due to decreased litigation costs during the 2020 three-month period. The increase for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily due to higher litigation costs, insurance increases and employee compensation in the first half of 2020.

Net loss for the three and nine months ended September 30, 2020 was $2,670,000 and $8,155,000, respectively, compared with a net loss of $1,780,000 and $324,000 for the three and nine months ended September 30, 2019, respectively, as a result of revenue and expenses described above.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus. Cocrystal employs unique, proprietary, structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the expected progress of, and the anticipated timing of achieving the value-driving milestones in, our coronavirus program, including the selection of a preclinical lead molecule in Q4 2020; the expected progress of, and the anticipated timing of achieving the value-driving milestones in, our Influenza A program, including the completion of the ongoing IND-enabling studies and commencement of Phase 1 clinical study in 2021; our expectations with respect to CC-42344 drug superiority; and the expected results of our collaboration with Merck, including the potential future milestone payments of up to $156,000,000 and royalties in connection with the collaboration. The words “believe,” “proceeds,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from the impact of the COVID-19 pandemic on the national and global economy and on our Company, including supply chain disruptions, our continued ability to proceed with our programs, our reliance on certain third parties, our reliance on continuing with Merck under the license and collaboration agreement, the future results of preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2019, as updated and supplemented by the Quarterly Reports on Form 10-Q for the quarters ended September 30, 2020 and June 30, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Additional factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor and Media Contact:

JTC Team, LLC
(833) 475-8247
[email protected]

Source: Cocrystal Pharma, Inc.

Pangaea Logistics Solutions Ltd. (PANL) – Surprising Reaction to 3Q2020 Results

Posted on by Admin

Monday, November 16, 2020

Pangaea Logistics Solutions Ltd. (PANL)

Surprising Reaction to 3Q2020 Results

Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk transportation services. It transports drybulk cargos including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite and limestone. The firm’s services include cargo loading, cargo discharge, vessel chartering, voyage planning and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Its strategy depends on focusing on increasing strategic contracts of affreightment, expanding capacity and flexibility by increasing its owned fleet and increasing backhaul focus and fleet efficiency.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Continuing to bounce back from challenging start to year with firmer 3Q2020 operating results. Unique and consistent business model delivered very high TCE rate outperformance, and the 3Q2020 environment for the dry bulk market improved. The unique business model once again delivered positive operating results, and adjusted 3Q2020 EBITDA improved to $15.1 million from $10.7 million in 2Q2020. While below expectations and last year, TCE rate outperformance remained solidly positive at $3,030/day, up from $2,187/day in 3Q2019.

    Adjusting 2020 EBITDA estimate to reflect 3Q2020 operating results and current dry bulk market conditions.  We were too optimistic on 3Q2020 operating results and are moving our EBITDA estimate down to $40.6 million, from our previous estimate of $45.1 million. Our estimate is based on higher TCE rates of $11,920/day (down from $12,260/day), which more than offset lower shipping days of 17,510 (down …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Newrange Gold (NRGOF)(NRG:CA) – Drilling Pauses to Allow for Receipt and Analysis of Assay Results

Posted on by Admin

Monday, November 16, 2020

Newrange Gold (NRGOF)(NRG:CA)

Drilling Pauses to Allow for Receipt and Analysis of Assay Results

As of April 24, 2020, Noble Capital Markets research on Newrange Gold is published under ticker symbols (NRGOF and NRG:CA). The price target is in USD and based on ticker symbol NRGOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Newrange Gold Corp is an exploration stage company focused on acquiring and exploring exploration and evaluation assets in Colombia and the United States. The Company operates in a single reportable operating segment-the acquisition, exploration, and development of mineral properties. Some of the projects acquired by the company are Pamlico gold project in Nevada and Rocky mountain project in Colorado. The company also holds an interest in the Yarumalito property, El Dovio property and Anori property in Colombia.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Significant progress to date. Since beginning the drilling program in late May, Newrange has drilled 65 holes for a total of 6,538 meters. Assay results for the last 26 holes are pending. Following a first phase of drilling that included 3,462 meters of drilling along Pamlico Ridge, drilling resumed on September 19 and the company drilled seven holes at Gold Box Canyon, seven holes in the Merritt area, eight drill holes at the Good Hope Mine, six holes at the Gold Bar and Pamlico Mines, and two drill holes on anomalies identified in an induced polarization (IP) survey. The company decided to take a break from drilling until the remaining assays results can be interpreted and a follow-up drilling program planned.

    More drilling planned.  Newrange expects to drill at least another 3,000 meters in approximately 20 holes that range in depth from 75 to 465 meters to follow up on recent drilling with multiple holes planned to test a large chargeability anomaly near the center of the property. Drilling is expected to resume on or about December 5 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

InPlay Oil (IPOOF)(IPO:CA) – The road to normal

Posted on by Admin

Monday, November 16, 2020

InPlay Oil (IPOOF)(IPO:CA)

The road to normal

As of April 24, 2020, Noble Capital Markets research on InPlay Oil is published under ticker symbols (IPOOF and IPO:CA). The price target is in USD and based on ticker symbol IPOOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQZ Exchange under the symbol IPOOF.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    IPO reported operating and financial results in line with expectations. Production of 3,742 boe/d vs. our 3,871 est. Oil prices were slightly below model ($39.51 vs $43.00) but gas prices were above ($2.32 vs $1.52). Sales of $10.8 mm vs. $10.9 mm. LOE of $14.42 vs. $14.18. Earnings of ($2.7 mm)/($0.04) vs. ($3.2 mm)/($0.05). All in all, a very straightforward quarter.

    Other developments were preannounced November 2.  InPlay’s $25 million bank loan is moving forward, a small $1.9 mm tuck-in acquisition closed, 4Q budget includes drilling 3 wells that will move production levels to pre-Covid rates of 5,000 boe/d. Only new development was that a ban on road construction will push drilling and the 5,000 target into the first quarter instead of year end …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Golden Predator Mining (NTGSF)(GPY:CA) – 2020 Drilling Program Completed Assay Results Pending

Posted on by Admin

Monday, November 16, 2020

Golden Predator Mining (NTGSF)(GPY:CA)

2020 Drilling Program Completed; Assay Results Pending

Golden Predator Mining Corp is a Canada based exploration stage company engaged in the business of acquiring and exploring mineral properties. It owns properties primarily in Yukon, Canada. Some of the company’s projects located in Yukon are the 3 Aces, Sprogge, Reef, Brewery Creek, Marg, Sonora Gulch, Grew Creek, Upper Hyland and others.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Assay results pending. Golden Predator completed its 2020 drilling program, which commenced in September, and included a reverse circulation drilling program, along with a metallurgical core drilling program. In aggregate, 60 holes were drilled representing 5,900 meters of drilling. Final assay results are expected in December. Drilling focused on connecting the Keg pit that combines the Canadian, Fosters, Golden and Kokanee deposits into one elongated pit with a fifth deposit known as Lucky. Core drilling samples will be used in leach column tests to confirm whether a coarser crush size results in better recoveries of gold.

    Bankable feasibility study (BFS) expected in Q1-21.  A BFS is being completed by Kappes Cassiday & Associates and will include a multi-year mine plan for the advancement of the Brewery Creek project. The BFS will include an inventory of material on the heap to be re-processed and a plan to resume mining of material from leachable resources contained within the licensed area …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

electroCore, Inc (ECOR) – 3Q Cost reduced Revenue Generation Continues

Posted on by Admin

Monday, November 16, 2020

electroCore, Inc. (ECOR)

3Q: Cost reduced, Revenue Generation Continues

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    3Q Results. electro’s 3Q20 results were uneventful. The company exited 3Q with $26 million in cash and marketable securities, which is expected to last through 2022. In the quarter, the company noted that it continues to generate revenue $1.1 million (+44% sequential growth compared to 2Q) with 2,881 total paid months of therapy (+17% compared to Q2). The net loss was $4.5 million with earnings per shares (EPS) of ($0.10) in the quarter.

    Model update.  We update our estimates to reflect slower revenue generation, reduce operating expenses, and shares outstanding. We now forecast $3.1 million, $6.5 million, and $10.7 million in revenues; ($0.62), ($0.45), and ($0.37) in EPS for F2020, F2021 and F2021, respectively. Our previous estimates were $4.7 million, $11.6 million, and $23.4 million in revenues and ($0.63), ($0.43), and ($0.22) …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Interest Rates Impact on Investment Sectors

Posted on by Admin

 

Winners and Losers as Interest Rates Shift Investor Focus

 

Treasury bonds sold-off pushing yields higher over the past week. The tech sector and other interest rate sensitive stocks felt downward pressure as individual investors and fund managers may have begun cutting their exposure. Experience tells us that when rates rise, particularly suddenly, tech stocks suffer. Technology shares have been prone to getting ahead of themselves since the 1990s. Last week saw selling in tech in part because of the precarious interest rate scenario.

A Quick Look Back

At the beginning of 2020 there was an 80bp spread between 1-month US Treasuries and the 30-year Treasury Bond. As of close of business last Friday the spread sat at 155bp. Although the entire yield curve has shifted lower, industries that make money on the spread between short deposit rates and longer lending rates benefit from the  wider spread and the amount of economic activity rather than the absolute level. This could include securities brokers where customers have large, uninvested balances, credit card companies, banks, and other finance companies.  

US Treasuries at Open of 2020 and November 2020  Daily Closing Yields

Source: www.treasury.gov

Activity This Past Week

Hope for a stronger economy ahead caused yields to rise after a release from Pfizer and BioNTech announcing a vaccine that achieved 90% efficacy against COVID-19. The 10-year US Treasury, responded by hitting .97% which is a seven-month high and later closed out the week at .89%.  According to data from the US Treasury all maturities past 1-year also posted a similar upward movement. This spooked some sectors as market participants considered the impact of higher rates on various industries that don’t do well as financing costs increase or bonds become an attractive alternative.

Yields are still 70-140bp below their start of the year and well below their 5-year average. Forward looking stock market participants last week lightened positions in  shares that ran up during the rally that pushed the S&P 500 up 58% from its March low.  

What May Lie Ahead

Expectations are that an economy that has been partially sedated to minimize spreading of a novel virus may resume more rapid growth moving forward. Higher economic activity would continue an already strong recovery trend as releases showing massive improvement in GDP and employment have beat expectations. A continuation of positive reports would reduce the need for the Fed to maintain rates at the low levels the FOMC now targets.  Higher overall rates could reduce profits for tech companies with high debt loads and industries where customers depend on financing such as the real estate and automotive industries. The popular list of companies that roared as people stayed home, (Zoom, Facebook, Peleton, Amazon, and others) are unlikely to achieve those levels of enthusiasm in a world less threatened by COVID-19.

. 

 

Suggested Reading:

How Will Remote Working Change After the Pandemic

Which Stocks Do Well After a Presidential Election

Many
Investors are Keeping Their Powder Dry

 

Do You Know a College Student?

Tell them about the College Challenge!

Sources:

https://robinhood.com/us/en/support/articles/earning-interest/

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

https://www.treasury.gov/resource-center/data-chart-center/interest-rates/pages/TextView.aspx?data=yieldYear&year=2020

PDS Biotechnology Corp (PDSB) – 3Q Update: Phase 2 Study in Head and Neck Cancer is Initiated

Posted on by Admin

Friday, November 13, 2020

PDS Biotechnology Corp (PDSB)

3Q Update: Phase 2 Study in Head and Neck Cancer is Initiated

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First company-sponsored Phase 2 study is initiated. PDS Biotechnology reported 3Q results and provided updates on the ongoing progress of its pipeline. The company initiated the first company-sponsored Phase 2 clinical trial VERSATILE 002 assessing PDS0101 in combination with checkpoint inhibitor Keytruda for the treatment of in first-line recurrent or metastatic, HPV16-positive head and neck cancers. Safety data is expected to complete in Q2 2021.

    Q3 2020 results.  In 3Q, PDS’s net loss was $3.9 million. In the 9-months of 2020, net loss was $10.9 million, which is in line with our estimates of $14.8 million in operating loss in F2020. The company ended the quarter with $33.5 million in cash and cash equivalents. Earnings per shares (EPS) loss was ($0.23) in the quarter. Updating shares outstanding, we now forecast ($0.91) in EPS in F2020 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

One Stop Systems Inc. (OSS) – 3Q Results Exceed Expectations

Posted on by Admin

Friday, November 13, 2020

One Stop Systems Inc. (OSS)

3Q Results Exceed Expectations

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems. The product line of the company includes GPU Appliances, GPU Expansion, GPUs and co-processors, Flash storage arrays, Flash storage expansion, Servers, Disk Arrays, Desktop computing appliances, accessories and parts. The company delivers high-end technology to customers through the sale of equipment and software for use on their premises or through remote cloud access to secure data centres housing technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    3Q20 Results. One Stop Systems reported third quarter revenue of $13 million, up 12% sequentially, down 13% y-o-y, and above guidance. Net income was up 57% to $858,000, or $0.05 per share. On an adjusted EPS basis, 3Q20 diluted EPS was $0.07 versus diluted adjusted EPS of $0.05 for 3Q19. Results exceed our and consensus expectations. We were at $12.5 million of revenue and EPS of $0.01, while consensus was $12.3 million and breakeven, respectively.

    COVID Impacts.  Management attempted to quantify the impact COVID has had on the top line. Year to date, revenues are running nearly $10 million below what management had projected at the beginning of the year. Nearly half of the shortfall is from OSS’ largest customer. On the positive side, most of this revenue should be recouped once the pandemic passes …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.